RecruitingNCT07343115
Familial Systemic Scleroderma
Sponsor
University Hospital, Strasbourg, France
Enrollment
20 participants
Start Date
Sep 2, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Studying familial forms of systemic scleroderma offers several advantages: 1. To better understand the pathophysiology of a complex autoimmune disease based on "extreme" cases (familial forms); 2. To identify potential molecular markers predictive of disease progression; 3. To identify potential pathophysiological targets for developing new therapies, particularly relevant in severe and refractory forms of the disease.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Adult subjects (≥ 18 years of age)
- Subjects diagnosed with systemic scleroderma by a clinician (including limited, diffuse, and sine scleroderma SSc, as well as overlap syndromes with myositis) and meeting at least the VEDOSS criteria: Raynaud's phenomenon + 1 other criterion from among: sausage fingers, antinuclear antibodies, scleroderma-specific antibodies (anti-centromere, anti-RNApolIII, anti-ScL70), capillaroscopic abnormalities
- At least one first-degree relative with systemic scleroderma meeting the same criteria
Exclusion Criteria1
- \- Subject who has expressed opposition to participating in the study
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07343115
Related Trials
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis
NCT043808311 location
Diffuse Cutaneous Scleroderma (DSSc) SFDI Study
NCT070902261 location
Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
NCT060569211 location